Pre-Exposure Prophylaxis for HIV Prevention

References

1. ↵
   1. Centers for Disease Control and Prevention (CDC)

   HIV/AIDS: Statistics Overview. CDC website. http://www.cdc.gov/hiv/statistics/overview/. Accessed June 1, 2016.
2. ↵
   CDC Vital Signs. Daily Pill Can Prevent HIV: Reaching People Who Could Benefit From PrEP. Atlanta, GA: Centers for Disease Control and Prevention; 2015. http://www.cdc.gov/vitalsigns/pdf/2015-11-24-vitalsigns.pdf. Accessed June 1, 2016.
3. ↵
   1. Department of Public Health, Epidemiology Section

   Facts and Figures: HIV/STI. North Carolina Health and Human Services website. http://epi.publichealth.nc.gov/cd/stds/figures.html. Accessed June 1, 2016.
4. ↵
   1. Grant RM,
   2. Lama JR,
   3. Anderson PL, et al., iPrEx Study Team

   Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-2599.

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   1. Choopanya K,
   2. Martin M,
   3. Suntharasamai P, et al., Bangkok Tenofovir Study Group

   Antiretroviral prophylaxis for HIV infection among people who inject drugs in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083-2090.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   1. Baeten JM,
   2. Donnell D,
   3. Ndase P, et al., Partners PrEP Study Team

   Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399-410.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   1. US Public Health Service

   Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2014: A Clinical Practice Guideline. Atlanta, GA: Centers for Disease Control and Prevention; 2014. http://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf. Accessed June 1, 2016.